Development  	Development  	 NN	O
of  	of  	 IN	O
inhibitors  	inhibitors  	 NN	O
in  	in  	 IN	O
haemophilia 	haemophilia 	 NN	O
.  	.  	 .	O
Ongoing  	Ongoing  	 JJ	B-NP
epidemiological  	epidemiological  	 NNS	I-NP
study  	study  	 VBP	O
A  	A  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
513  	513  	 CD	O
consecutive  	consecutive  	 JJ	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
494-haemophilia  	494-haemophilia  	 NNP	O
A  	A  	 NNP	O
and  	and  	 CC	O
19-haemophilia  	19-haemophilia  	 NNP	O
B 	B 	 NNP	O
)  	)  	 -RRB-	O
from  	from  	 IN	O
eight  	eight  	 CD	O
haemophilia  	haemophilia  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
centers  	centers  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
investigated  	investigated  	 VBN	O
with  	with  	 IN	O
Bethesda  	Bethesda  	 NNP	B-NP
assay  	assay  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
presence  	presence  	 NN	O
of  	of  	 IN	O
factor  	factor  	 NN	B-NP
VIII  	VIII  	 NNP	I-NP
or  	or  	 CC	O
IX  	IX  	 CD	O
inhibitors 	inhibitors 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
overall  	overall  	 JJ	O
prevalence  	prevalence  	 NN	O
of  	of  	 IN	O
inhibitors  	inhibitors  	 NN	O
was  	was  	 VBD	O
15.20 	15.20 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
18.48 	18.48 	 CD	O
%  	%  	 NN	O
in  	in  	 IN	O
severe 	severe 	 JJ	O
,  	,  	 ,	O
5.60 	5.60 	 CD	O
%  	%  	 NN	O
in  	in  	 IN	O
moderate  	moderate  	 JJ	O
and  	and  	 CC	O
12.24 	12.24 	 CD	O
%  	%  	 NN	O
in  	in  	 IN	O
mild  	mild  	 JJ	O
forms 	forms 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
prevalence  	prevalence  	 NN	O
was  	was  	 VBD	O
higher  	higher  	 JJR	O
than  	than  	 IN	O
reported  	reported  	 VBN	O
in  	in  	 IN	O
most  	most  	 JJS	O
of  	of  	 IN	O
the  	the  	 DT	O
western  	western  	 JJ	O
countries 	countries 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
age  	age  	 NN	O
at  	at  	 IN	O
start  	start  	 NN	O
of  	of  	 IN	O
substitution  	substitution  	 NNS	B-NP
( 	( 	 -LRB-	O
p  	p  	 CD	O
=  	=  	 SYM	O
0.9775 	0.9775 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
the  	the  	 DT	O
frequent  	frequent  	 JJ	O
switching  	switching  	 NN	O
of  	of  	 IN	O
factor  	factor  	 NN	B-NP
concentrates  	concentrates  	 NNS	I-NP
( 	( 	 -LRB-	O
p  	p  	 CD	O
=  	=  	 SYM	O
0.8931 	0.8931 	 CD	O
)  	)  	 -RRB-	O
were  	were  	 VBD	O
not  	not  	 RB	O
relevant  	relevant  	 JJ	O
factors  	factors  	 NNS	O
for  	for  	 IN	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
inhibitors 	inhibitors 	 NN	O
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
worth  	worth  	 JJ	O
to  	to  	 TO	O
be  	be  	 VB	O
mentioned  	mentioned  	 VBN	O
the  	the  	 DT	O
unexpectedly  	unexpectedly  	 JJ	O
occurrence  	occurrence  	 NN	O
of  	of  	 IN	O
inhibitors  	inhibitors  	 NN	O
in  	in  	 IN	O
prior  	prior  	 JJ	O
inhibitor  	inhibitor  	 JJ	O
negative  	negative  	 JJ	O
( 	( 	 -LRB-	O
6 	6 	 CD	O
/ 	/ 	 CD	O
72 	72 	 CD	O
)  	)  	 -RRB-	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
during  	during  	 IN	O
surgical  	surgical  	 JJ	B-NP
interventions 	interventions 	 NNS	I-NP
)  	)  	 -RRB-	O
probably  	probably  	 RB	O
due  	due  	 JJ	O
to  	to  	 TO	O
their  	their  	 PRP$	O
previous  	previous  	 JJ	O
scarce  	scarce  	 JJ	O
substitution 	substitution 	 NN	B-NP
,  	,  	 ,	O
occurrence  	occurrence  	 NN	O
which  	which  	 WDT	O
seems  	seems  	 VBZ	O
not  	not  	 RB	O
being  	being  	 VBG	O
connected  	connected  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
continuous  	continuous  	 JJ	B-NP
infusion  	infusion  	 NN	I-NP
modality  	modality  	 NN	I-NP
of  	of  	 IN	I-NP
factor  	factor  	 NN	I-NP
VIII  	VIII  	 NNP	I-NP
administration  	administration  	 NN	I-NP
( 	( 	 -LRB-	O
p  	p  	 CD	O
=  	=  	 SYM	O
0.8341 	0.8341 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
controversial  	controversial  	 JJ	B-NP
situations 	situations 	 NNS	I-NP
,  	,  	 ,	O
in  	in  	 IN	O
the  	the  	 DT	O
field  	field  	 NN	O
of  	of  	 IN	O
low  	low  	 JJ	O
titer  	titer  	 NNS	B-NP
( 	( 	 -LRB-	O
≤  	≤  	 CD	O
1  	1  	 CD	O
BU 	BU 	 CD	B-NP
/ 	/ 	 CD	I-NP
ml 	ml 	 CD	I-NP
)  	)  	 -RRB-	O
inhibitors  	inhibitors  	 NN	O
for  	for  	 IN	O
a  	a  	 DT	O
reliable  	reliable  	 JJ	O
interpretation  	interpretation  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
results  	results  	 NNS	O
the  	the  	 DT	O
performance  	performance  	 NN	O
of  	of  	 IN	O
recovery  	recovery  	 NN	B-NP
index  	index  	 NN	I-NP
and  	and  	 CC	O
half-life  	half-life  	 NN	B-NP
time  	time  	 NN	I-NP
assessment  	assessment  	 NN	I-NP
of  	of  	 IN	I-NP
FVIII 	FVIII 	 NNP	I-NP
/ 	/ 	 NNP	I-NP
IX  	IX  	 NNP	I-NP
was  	was  	 VBD	O
undertaken 	undertaken 	 VBN	O
.  	.  	 .	O
